The value of multimodal imaging with 123I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia

[1]  R. Petersen,et al.  Subtypes of dementia with Lewy bodies are associated with α-synuclein and tau distribution , 2020, Neurology.

[2]  B. Boeve,et al.  Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders , 2020, The Journal of Nuclear Medicine.

[3]  David T. Jones,et al.  β-Amyloid PET and neuropathology in dementia with Lewy bodies , 2019, Neurology.

[4]  Jacquelyn Elizabeth Brogley.  DaTQUANT: The Future of Diagnosing Parkinson Disease , 2019, The Journal of Nuclear Medicine Technology.

[5]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[6]  H. Hanyu,et al.  Comparison of diagnostic utility of semi-quantitative analysis for DAT-SPECT for distinguishing DLB from AD , 2017, Journal of the Neurological Sciences.

[7]  Alan J. Thomas,et al.  Autopsy validation of 123I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB , 2017, Neurology.

[8]  C. Jack,et al.  A large-scale comparison of cortical thickness and volume methods for measuring Alzheimer's disease severity , 2016, NeuroImage: Clinical.

[9]  Aldo Quattrone,et al.  CADA—computer-aided DaTSCAN analysis , 2016, EJNMMI Physics.

[10]  Matthew L Senjem,et al.  Dementia with Lewy bodies , 2014, Neurology.

[11]  J. O'Brien,et al.  The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies , 2013, Psychological Medicine.

[12]  H. Zaidi,et al.  Regions of Interest–Based Discriminant Analysis of DaTSCAN SPECT and FDG-PET for the Classification of Dementia , 2013, Clinical nuclear medicine.

[13]  C. Jack,et al.  Multimodality imaging characteristics of dementia with Lewy bodies , 2012, Neurobiology of Aging.

[14]  J. O'Brien,et al.  Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. , 2012, Brain : a journal of neurology.

[15]  Clifford R. Jack,et al.  Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies , 2012, Neurobiology of Aging.

[16]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[17]  John Seibyl,et al.  SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0* , 2012, The Journal of Nuclear Medicine.

[18]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[19]  N. Cairns,et al.  Amyloid imaging of Lewy body‐associated disorders , 2010, Movement disorders : official journal of the Movement Disorder Society.

[20]  C. Rowe,et al.  The 18F-FDG PET Cingulate Island Sign and Comparison to 123I-β-CIT SPECT for Diagnosis of Dementia with Lewy Bodies , 2009, Journal of Nuclear Medicine.

[21]  C. Jack,et al.  Comparison of 18F-FDG and PiB PET in Cognitive Impairment , 2009, Journal of Nuclear Medicine.

[22]  C. Rowe,et al.  Amyloid load in Parkinson’s disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.

[23]  Keith A. Johnson,et al.  Imaging amyloid deposition in Lewy body diseases , 2008, Neurology.

[24]  C. Jack,et al.  11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. , 2008, Brain : a journal of neurology.

[25]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[26]  K. Jellinger,et al.  Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease , 2008, Acta Neuropathologica.

[27]  Brian B. Avants,et al.  Symmetric diffeomorphic image registration with cross-correlation: Evaluating automated labeling of elderly and neurodegenerative brain , 2008, Medical Image Anal..

[28]  I. McKeith,et al.  Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study , 2007, The Lancet Neurology.

[29]  I. McKeith,et al.  Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[30]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[31]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[32]  Karl J. Friston,et al.  Unified segmentation , 2005, NeuroImage.

[33]  E. David Williams,et al.  The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease , 2004, NeuroImage.

[34]  D W Dickson,et al.  DLB fluctuations , 2004, Neurology.

[35]  Emma J. Burton,et al.  Patterns of Cerebral Atrophy in Dementia with Lewy Bodies Using Voxel-Based Morphometry , 2002, NeuroImage.

[36]  Z Walker,et al.  Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand , 2002, Journal of neurology, neurosurgery, and psychiatry.

[37]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[38]  Satoshi Minoshima,et al.  Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation , 2001, Annals of neurology.

[39]  R. Hamilton,et al.  Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry , 2000, Brain pathology.

[40]  Nobuyuki Okamura,et al.  Glucose Hypometabolism and Neuropathological Correlates in Brains of Dementia with Lewy Bodies , 2000, Experimental Neurology.

[41]  I G McKeith,et al.  MRI volumetric study of dementia with Lewy bodies , 2000, Neurology.

[42]  I G McKeith,et al.  Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. , 1999, Brain : a journal of neurology.

[43]  K. Ishii,et al.  Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease , 1998, Neurology.

[44]  R. Albin,et al.  Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease , 1996, Neurology.

[45]  C. Clark,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1994, Neurology.

[46]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[47]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[48]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[49]  C. P. Hughes,et al.  A New Clinical Scale for the Staging of Dementia , 1982, British Journal of Psychiatry.

[50]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[51]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.

[52]  L. Seeberger,et al.  Examination of the UPDRS bradykinesia subscale: equivalence, reliability and validity. , 2011, Journal of Parkinson's disease.

[53]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[54]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .